Biorez™ Raises $3.5 Million to Close Out $7 Million in Seed Financing

Company launches biorez.com featuring its new BioBrace™ technology

SEPTEMBER 09, 2020

Biorez, Inc., a medical device company advancing tendon and ligament repair, announced today that it has raised $3.5 million in its Series Seed financing, adding to $3.5 million raised previously. The financing round was led by New York Angels, with participation from Connecticut Innovations, Pritzker Vlock Family Office, Brainchild Holdings, and The Vertical Group.

Biorez has pioneered the BioBrace™ implant, a breakthrough material featuring a highly porous collagen sponge reinforced with bioresorbable microfilaments. The BioBrace implant is intended to augment and reinforce a wide range of tendon and ligament procedures, including rotator cuff repair and ACL reconstruction.

“Our vision is to help patients return to normal activity sooner and safer,” said Kevin Rocco, President and CEO of Biorez. “BioBrace has the potential to create a new category of implant materials known as “biocomposites” that contain both biologic and synthetic materials. This rationally-designed approach creates an opportunity for more durable surgical repairs and faster healing, which we intend to prove clinically.”

Concurrent with this financing, Biorez is also announcing the release of a new company website (http://www.biorez.com) that provides additional information about its innovative BioBrace technology.

About Biorez:
Biorez is a New Haven-based medical device start-up focused on advancing tendon and ligament repair using its proprietary BioBrace™ technology. Biorez’s products are in the development stage and have not been approved for use by any regulatory agency including the US Food and Drug Administration.